Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion driver mutations are sometimes seen in NSCLC, particularly in patients with adenocarcinoma, young and low-risk patients, and occasionally in patients with signet ring histology. Dr. Bauman states platinum doublet chemotherapy was once the NSCLC standard of care, but with recent advancements, RET-fusion mutations are being targeted by tyrosine kinase inhibitors for a more personalized approach.

Read the full video transcript by clicking here.